Disappointed by lackluster data, Inspire Pharmaceuticals has abandoned development of its epinastine nasal spray for the treatment of seasonal allergic rhinitis. Subjects treated with the nasal spray did not achieve better outcomes than those treated with placebo. In a statement, CEO Christy Shaffer said that the company won't devote any more resources to development of the spray, and that Inspire would focus on other programs. Those include a Phase III program for dry eye, another Phase III program for cystic fibrosis, and and Phase I glaucoma study.
- take a look at Inspire's release
Inspire bails on $89M allergy pact
Inspire gets $75M injection from Warburg Pincus
Inspire wins fed's approval of eye infection therapy
Inspire licenses anti-infective for $13M upfront